Has the time come for cost-effectiveness analysis in US health care?

Health Economics, Policy and Law

Volumn 4, Issue 4, 2009, Pages 425-443

  Bryan, Stirling ^b   Sofaer, Shoshanna ^c   Siegelberg, Taryn ^a   Gold, Marthe ^a  

^a CITY COLLEGE OF NEW YORK   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; KNOWLEDGE; MEDICARE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; PUBLIC HEALTH SERVICE; UNITED STATES;

ADULT; AGED; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; EDUCATION; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; UNITED STATES;

EID: 70350731252     PISSN: 17441331     EISSN: 1744134X     Source Type: Journal    
DOI: 10.1017/S1744133109004885     Document Type: Article

References (51)

1. Aaron, H., W. Schwartz, and M. Cox (2005), Can We Say No? The Challenge of Rationing Health Care, Washington, DC: Brookings Institution Press.
2. Al, M.J., T. Feenstra, and W.B. Brouwer (2004), 'Decision makers' views on health care objectives and budget constraints: Results from a pilot study', Health Policy, 70(1): 33-48.
3. Aspinall, S.L., C.B. Good, P.A. Glassman, and M.A. Valentino (2005), 'The evolving use of cost-effectiveness analysis in formulary management within the department of veterans affairs', Medical Care, 43 (7 Suppl), 20-26.
4. Banta, H.D. and B.R. Luce (1983), 'Assessing the cost-effectiveness of prevention', Journal of Community Health, 9(2): 145-165.
5. Bell, C.M., D.R. Urbach, J.G. Ray, A. Bayoumi, A.B. Rosen, D. Greenberg, and P.J. Neumann (2006), 'Bias in published cost effectiveness studies: systematic review', British Medical Journal, 332(7543): 699-703.
6. Bloche, M.G. and P.D. Jacobson. (2000), 'The Supreme Court and bedside rationing', Journal of the American Medical Association, 284 (21): 2776-2779.
7. Brock, D. (1998), 'Ethical issues in the development of summary measures of population health status', in Institute of Medicine (ed.), Summarizing Population Health: Directions for the Development and Application of Population Metrics, Washington, DC: National Academy Press, pp. 73-91.
8. Bryan, S., I.P. Williams, and S. McIver (2007), 'Seeing the NICE side of cost-effectiveness analysis: A qualitative investigation of the use of CEA in NICE technology appraisals', Health Economics, 16 (2), 179-193.
9. Daniels, N. (1985), Just Health Care, editor D. Walker, Cambridge MA: Harvard University Press.
10. Daniels, N. and J. Sabin (2002), Setting Limits Fairly: Can We Learn to Share Medical Resources? New York: Oxford University Press.
11. Foote, S.B. (2002), 'Why Medicare cannot promulgate a national coverage rule: A case of regulamortis', Journal of Health Politics, Policy and Law, 27(5): 707-730.
12. Garber, A.M. (2001), 'Evidence-based coverage policy', Health Affairs (Millwood), 20(5): 62-82.
13. Garber, A.M. (2004), 'Cost-effectiveness and evidence evaluation as criteria for coverage policy', Health Affairs (Millwood) Suppl Web Exclusives (W4): 284-296.
14. Gillick, M.R. (2004), 'Medicare coverage for technological innovations - time for new criteria?', New England Journal of Medicine, 350 (21): 2199-2203.
15. Gold, M.R., D. Stevenson, and D.G. Fryback (2002), 'HALYS and QALYS and DALYS, oh my: Similarities and differences in summary measures of population health', Annual Review of Public Health, 23: 115-134.
16. Gold, M.R., P. Franks, T. Siegelberg, and S. Sofaer (2007), 'Does providing cost-effectiveness information change coverage priorities for citizens acting as social decision makers?', Health Policy, 83 (1): 65-72.
17. Gold, M.R., S. Sofaer, and T. Siegelberg (2007), 'Medicare and cost-effectiveness analysis: Time to ask the taxpayers', Health Affairs, 26(5): 1399-1406.
18. Hadorn, D.C. (1991), 'Setting health care priorities in Oregon: cost-effectiveness meets the rule of rescue', Journal of the American Medical Association, 265(17): 2218-2225.
19. Harris, J. (1987), 'QALYfying the value of life', Journal of Medical Ethics, 13(3): 117-123.
20. Harris, J. (1988), 'Life: Quality, value and justice', Health Policy 10(3): 259-266.
21. Henry, D.A., S.R. Hill, and A. Harris (2005), 'Drug prices and value for money: The Australian Pharmaceutical Benefits Scheme', Journal of the American Medical Association, 294(20): 2630-2632.
22. Jacobson, P.D. and M.L. Kanna (2001), 'Cost-effectiveness analysis in the courts: Recent trends and future prospects', Journal of Health Politics, Policy and Law, 26(2): 291-326.
23. Jones, S.B. (1996), 'Medicare influence on private insurance: Good or ill?', Health Care Financing Review, 18(2): 153-161.
24. Kassirer, J.P. and M. Angell (1994), 'The journal's policy on cost-effectiveness analyses', New England Journal of Medicine, 331(10): 669-670.
25. Koch, T. (2000), 'Life quality v. the "quality of life": Assumptions underlying prospective quality of life instruments in health care planning', Social Science and Medicine, 51(3): 419-427.
26. Luce, B.R. (2005), 'What will it take to make cost-effectiveness analysis acceptable in the United States?', Medical Care, 43 (7 Suppl): 44-48.
27. Menzel, P., M.R. Gold, E. Nord, J.L. Pinto-Prades, J. Richardson, and P. Ubel (1999), 'Toward a broader view of values in cost-effectiveness analysis of health', Hastings Center Report, 29(3): 7-15.
28. Miners, A.H., M. Garau, D. Fidan, and A.J. Fischer (2005), 'Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organizations: Retrospective study', British Medical Journal, 330(7482): 65.
29. Neumann, P.J. (2004a), 'Evidence-based and value-based formulary guidelines', Health Affairs (Millwood), 23(1): 124-134.
30. Neumann, P.J. (2004b), 'Why don't Americans use cost-effectiveness analysis?', American Journal of Managed Care, 10(5): 308-312.
31. Neumann, P.J., A.B. Rosen, and M.C. Weinstein (2005), 'Medicare and cost-effectiveness analysis', New England Journal of Medicine, 353(14): 1516-1522.
32. Neumann, P. (2005), Using Cost-Effectiveness Analysis to Improve Health Care, New York, NY: Oxford University Press.
33. Neumann, P.J., J.A. Palmer, N. Daniels, K. Quigley, M.R. Gold, and S. Chao, for the Panel on Integrating Cost-Effectiveness Considerations into Health Policy Decisions (2008), 'A strategic plan for integrating cost-effectiveness analysis into the US healthcare system', American Journal of Managed Care, 14(4): 185-188.
34. Nord, E., J.L. Pinto, J. Richardson, P. Menzel, and P. Ubel (1999), 'Incorporating societal concerns for fairness in numerical valuations of health programmes',Health Economics, 8(1): 25-39.
35. Prosser, L.A., J.P. Koplan, P.J. Neumann, and M.C. Weinstein (2000), 'Barriers to using cost-effectiveness analysis in managed care decision making', American Journal of Managed Care, 6(2): 173-179.
36. Rawles, J. (1989), 'Castigating QALYs', Journal of Medical Ethics, 15(3): 143-147.
37. Reinhardt, U.E. (1997), 'Making economic evaluations respectable', Social Science and Medicine, 45(4): 555-562.
38. Rawlins, M. (1999), 'In pursuit of quality: The National Institute for Clinical Excellence', Lancet, 353(9158): 1079-1082.
39. Rawlins, M.D. (2005), 'Pharmacopolitics and deliberative democracy', Clinical Medicine, 5 (5): 471-475.
40. Ross, J. (1995), 'The use of economic evaluation in health care: Australian decision makers' perceptions', Health Policy, 31 (2): 103-110.
41. Russell, L.B., M.R. Gold, J.E. Siegel, N. Daniels, and M.C. Weinstein (1996), 'The role of cost-effectiveness analysis in health and medicine: panel on Cost-Effectiveness in Health and Medicine', Journal of the American Medical Association, 276(14): 1172-1177.
42. Sacramento Healthcare Decisions. (2006), 'Getting good value: Consumers debate costly treatments: Is it worth the expense?', Available at http://www.sachealthdecisions.org/docs/ggv_report.pdf
43. Saha, S., T.J. Hoerger, M.P. Pignone, S.M. Teutsch, M. Helfand, and J.S. Mandelblatt (2001), 'The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services', American Journal of Preventative Medicine, 20(3 Suppl): 36-43.
44. Schauffler, H.H. (1993), 'Disease prevention policy under Medicare: A historical and political analysis', American Journal of Preventative Medicine, 9(2): 71-77.
45. Siegel, J.E. (2005), 'Cost-effectiveness analysis in US healthcare decision-making: Where is it going?', Medical Care, 43(7 Suppl): 1-4.
46. Task Force on Principles for Economic Analysis of Health Care Technology (1995), 'Economic analysis of health care technology: A report on principles', Annals of Internal Medicine, 123(1): 61-70.
47. Tunis, S.R. (2004), 'Why Medicare has not established criteria for coverage decisions', New England Journal of Medicine, 350 (21): 2196-2198.
48. Tunis, S.R. (2007), 'Reflections on science, judgment, and value in evidence-based decision making: A conversation with David Eddy', Health Affairs, Web Exclusive, 19 June 2007, w500-w515.
49. US Congress (1992), 'Evaluation of the Oregon medicaid proposal', in OTA-H-531, Office of Technology Assessment, Washington, DC: US Congress.
50. Wallace, J.F., S.R. Weingarten, C.F. Chiou, J.M. Henning, A.A. Hohlbauch, M.S. Richards, N.S. Herzog, L.S. Lewensztain, and J.J. Ofman (2002), 'The limited incorporation of economic analyses in clinical practice guidelines', Journal of General Internal Medicine, 17 (3): 210-220.
51. WellPoint (2005), National Pharmacy and Therapeutics Committee, www.wellpointnextrx.com/shared/noapplication/f1/s0/t0/pw_ad080613.pdf